Watch Bajaj Healthcare Limited for free: we tell you when fair value or trend changes.

Bajaj Healthcare Limited (BAJAJHCARE) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Bajaj Healthcare Limited stock ₹89.36, price ₹325, that is 72.5% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

16 models, one by oneBear ₹86.15 to bull ₹111.78 Growth analysisrevenue history, year by year Quality 41/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE411U01027

Broad data Nov 7, 2026

Bajaj Healthcare Limited

BAJAJHCARE · NSE

Very expensive, weak quality

Our calculation puts a fair price 73% below what the stock costs today.

Low debt

Broad data

Revenue last quarter +19% vs. a year ago.

Quality 41/100

Thin margins · 3.1% net margin (TTM)

0.5% dividend yield · Token dividend

Fair value ₹89.36 · Strongly overvalued

Weak Growth (revenue 5y −1.4 %/yr in INR)

Negative free cash flow

Trails peers (4/13)

Narrow moat 34/100 · thin data

Watch Bajaj Healthcare Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range ₹259.48 – ₹710.53 · fair‑value band ₹86.15 – ₹111.78 · the ₹325.35 price screens above the ₹89.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Bajaj Healthcare in your weekly email

Every Wednesday you see whether Bajaj Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally.

Show moreShow less

The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals.

It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 " amino " 1 " adamantanol, N " boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide).

In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.

Stock analysis

Bajaj Healthcare Limited (BAJAJHCARE) currently trades at ₹325.35, while our model-based Fair Value estimate is ₹89.36, 73% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Multiples group reads highest at a median of ₹281.58 per share, and 3 of the 16 models we run sit above the ₹325.35 price.

Bear case: the Dividend Discount group reads lowest at ₹9.39, and 13 of the 16 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹86.15 (bear) to ₹111.78 (bull), the price of ₹325.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Bajaj Healthcare Limited reported revenue of ₹6.1B in FY2026 versus ₹6.8B in FY2022, a compound −2.6%/yr. Reported net income was ₹158M in FY2026, compounding −31.4%/yr from FY2022.

Key figures

Market cap ₹11.0B (≈ $117M) Micro · P/E ratio 44.0 · P/S ratio 1.67 · EPS (TTM) ₹7.39 · Dividend yield 0.5% · Net margin 3.1% · Return on equity 4.8% · Return on assets (EBIT) 9.3% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (low confidence).

What moves the price

The share trades about 28% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at −73%, BAJAJHCARE screens richer than that median.

Fair Value models

Bear ₹86.15 Fair Value ₹89.36 Bull ₹111.78

Price ₹325.35 · Downside -72.5%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹3.65 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

Residual Income ₹86.15 ₹89.36 ₹98.38 76

EPV ₹131.73 ₹146.30 ₹157.91 74

ROIC Compounder ₹131.73 ₹146.30 ₹157.91 72

All 16 models by family

Earnings-Based

Graham-Dodd ₹31.85 ₹136.64 ₹186.70 64

Lynch FV ₹40.32 ₹57.60 ₹74.88 61

PEG = 1.0 ₹40.32 ₹57.60 ₹74.88 57

EPV ₹131.73 ₹146.30 ₹157.91 74

Dividend Discount

Gordon GGM ₹5.98 ₹9.52 ₹11.91 69

DDM Multi-Stage ₹5.98 ₹9.25 ₹10.28 67

Multiples

P/E Multiple ₹77.27 ₹103.03 ₹128.79 63

P/S Multiple ₹59.71 ₹79.61 ₹99.52 58

P/B Multiple ₹339.84 ₹453.12 ₹566.41 55

EV/EBIT ₹229.94 ₹327.48 ₹425.03 65

EV/EBITDA ₹264.21 ₹373.19 ₹482.16 67

EV/Revenue ₹146.16 ₹235.67 ₹325.19 53

Asset-Based

NCAV (Graham) ₹35.07 ₹53.13 ₹66.41 54

Economic Profit

Residual Income ₹86.15 ₹89.36 ₹98.38 76

ROIC Compounder ₹131.73 ₹146.30 ₹157.91 72

Growth Earnings

Growth-Adj P/E ₹60.19 ₹85.99 ₹111.78 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31

How much profit the company makes from its sales and capital

Quality Growth 41

Are margins and returns getting better?

Cashflow 36

Do the profits arrive as real cash?

Financial strength 59

Debt, balance sheet and risk of trouble

Investment 67

Does it invest with discipline instead of growing at any price?

Low Volatility 70

How calm the share price moves, does not count

Price momentum 34

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 17

Distance to the 52-week high, does not count

New shares 21

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 21/100

Revenue growth is weak: less than 2 % a year.

Revenue growth 1 year

+12.6%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−1.8%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−1.4%

Start year 2021 (pandemic). Over 10 years: +10.6% a year

Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+11.5%

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

’26

What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

−9.3%

Earnings growth per share plus dividend.

Earnings per share, growth per year−9.8%

Dividend (yield on the price)0.5%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−29.0% vs 5.1%, slowing

Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 13%

Pace: the 5-year rate starts in 2021 (pandemic)

BAJAJHCARE screens overvalued: fair value 73% below the price. Compare with Merck KGaA →

Compare Bajaj Healthcare Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks

Beats the industry median on 4/13 measures

Overall it trails its industry peers.

Valuation

Quality Score 41 · Bottom 25%

Fair Value upside −72.5% · Bottom 25%

Profitability

Return on equity (12 months) 4.8% · Below median

Return on assets 1.7% · Below median

Net margin (12 months) 3.1% · Below median

Operating margin (12 months) 13.4% · Above median

Growth and dividend

Revenue growth (quarter YoY) 18.9% · Top 25%

Dividend yield (12 months) 0.5% · Bottom 25%

Balance sheet

Debt / equity 0.09× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 44.0× · Priciest 25%

P/B 2.06× · Pricier than median

P/S (12 months) 1.67× · Cheaper than median

EV/EBITDA 10.1× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 18

FUTURE (revenue growth)95 · sector 25

PAST (return on equity)19 · sector 25

HEALTH (low debt)96 · sector 96

DIVIDEND (yield)9 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Zoetis Inc ZTS	$82.57	$113.53	+38%	vs BAJAJHCARE
Jiangsu Hengrui Pharmaceuticals Co 600276	¥48.22	¥53.04	+10%	vs BAJAJHCARE
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,902	₹1,983	+4%	vs BAJAJHCARE
Haleon plc HLN	$9.10	$8.62	−5%	vs BAJAJHCARE
Merck KGaA MRK	€151.60	€109.18	−28%	vs BAJAJHCARE
Galderma Group GALD	CHF 194.95	CHF 109.80	−44%	vs BAJAJHCARE
Takeda Pharmaceutical Company TAK	$20.84	$11.34	−46%	vs BAJAJHCARE
Teva Pharmaceutical Industries Limited TEVA	$43.24	$20.74	−52%	vs BAJAJHCARE
Sandoz Group SDZ	CHF 85.20	CHF 40.54	−52%	vs BAJAJHCARE
Divi's Laboratories Limited DIVISLAB	₹11,367	₹1,567	−86%	vs BAJAJHCARE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks Stocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bajaj Healthcare Limited: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/BAJAJHCARE?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/BAJAJHCARE.NSE.svg" width="360" height="84" alt="Bajaj Healthcare Limited: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "Bajaj Healthcare Limited Fair Value". https://www.fairvalue-calculator.com/stock/BAJAJHCARE

Frequently asked questions

Is Bajaj Healthcare Limited (BAJAJHCARE) overvalued or undervalued?

As of Nov 7, 2026, our model estimates a fair value of ₹89.36 versus a price of ₹325.35, about 73% lower (overvalued).

What is the fair value of BAJAJHCARE?

Our model-based fair value for Bajaj Healthcare Limited is ₹89.36 (as of Nov 7, 2026), built from audited fundamentals. The current price: ₹325.35.

What is the quality score of BAJAJHCARE?

Bajaj Healthcare Limited has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Bajaj Healthcare Limited (BAJAJHCARE)?

Our model-based price target is the fair value of ₹89.36 (as of Nov 7, 2026) from 16 valuation models. Cautious scenario ₹86.15, optimistic scenario ₹111.78. It is a calculation from audited fundamentals, not an analyst target.

What is the Bajaj Healthcare Limited stock forecast for 2026?

Our models put fair value at ₹89.36, about 73% lower versus a price of ₹325.35 (overvalued). Cautious scenario ₹86.15, optimistic scenario ₹111.78. The calculation is refreshed regularly with new filings.

What is the revenue of Bajaj Healthcare Limited (BAJAJHCARE)?

Bajaj Healthcare Limited reported trailing-twelve-month revenue of about ₹6.6B (latest available figure, as of Nov 7, 2026).

Does Bajaj Healthcare Limited pay a dividend?

Bajaj Healthcare Limited currently shows a dividend yield of 0.46% relative to its recent price (as of Nov 7, 2026).

How much is the dividend of Bajaj Healthcare Limited (BAJAJHCARE) and when is the ex-dividend date?

Bajaj Healthcare Limited pays a dividend of ₹1.50 per share a year, a dividend yield of 0.5%. The last ex-dividend date was Sep 11, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 20.3% of earnings. Our assessment: Token dividend. At a yield of 0.5% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.5% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.

What is the intrinsic value of Bajaj Healthcare Limited (BAJAJHCARE)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bajaj Healthcare Limited it is ₹89.36 per share (as of Nov 7, 2026), against a price of ₹325.35. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).

Is Bajaj Healthcare Limited stock overvalued or undervalued in 2026?

As of Nov 7, 2026, BAJAJHCARE trades above its calculated fair value: price ₹325.35, fair value ₹89.36, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of BAJAJHCARE?

No. The price is what the market pays today (₹325.35); the fair value is what the company's own numbers justify (₹89.36). For Bajaj Healthcare Limited the two are ₹235.99 per share apart. That gap is exactly why we show both numbers side by side.

How much is Bajaj Healthcare Limited worth?

The market values Bajaj Healthcare Limited at about ₹11.0B (market capitalisation, as of Nov 7, 2026). Per share that is ₹325.35; our models calculate a fair value of ₹89.36 per share.

What do the bullish and bearish scenarios say about BAJAJHCARE?

Our models span a range for Bajaj Healthcare Limited: cautious scenario ₹86.15, base ₹89.36, optimistic ₹111.78 per share (as of Nov 7, 2026, price ₹325.35). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of BAJAJHCARE?

Bajaj Healthcare Limited trades at a price-to-earnings ratio of 44.0 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹89.36 is built from several models across several years. Other multiples: P/B 2.1, P/S 1.7, EV/EBITDA 10.1.

How solid is the balance sheet of Bajaj Healthcare Limited (BAJAJHCARE)?

Balance-sheet figures for Bajaj Healthcare Limited (as of Nov 7, 2026): return on equity 4.8%, debt of 0.09 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.

How far is BAJAJHCARE from its 52-week high?

Bajaj Healthcare Limited trades at ₹325.35, about 28% below its 52-week high of ₹449.20 and 18% above the low of ₹274.95 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of ₹89.36 is for.

Which stocks are comparable to Bajaj Healthcare Limited?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Bajaj Healthcare Limited stock attractive at the current price?

The data as of Nov 7, 2026: price ₹325.35, calculated fair value ₹89.36 (−73%), Quality Score 41/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of BAJAJHCARE calculated?

We run Bajaj Healthcare Limited through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹89.36 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.0% above its aggregate fair value. Bajaj Healthcare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Bajaj Healthcare Limited (BAJAJHCARE)?

The closing price on Nov 11, 2026 was ₹325.35. Our model-based fair value is ₹89.36, about 73% lower (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Bajaj Healthcare Limited right now?

The price sits above even our optimistic bull case (₹111.78). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.

Where does the earnings growth of Bajaj Healthcare Limited (BAJAJHCARE) come from?

Earnings per share at Bajaj Healthcare Limited grew +11.9 % a year from 2015 to 2026. Broken into its drivers: revenue per share +8.2 %, EBIT margin +2.4 %, tax rate +3.6 %, residual (interest, one-offs) −2.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Bajaj Healthcare Limited

How large is the market capitalisation of Bajaj Healthcare Limited (BAJAJHCARE)?

The market capitalisation of Bajaj Healthcare Limited is ₹11.0B (≈ $117M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Bajaj Healthcare Limited (BAJAJHCARE)?

The price-to-sales ratio of Bajaj Healthcare Limited is 1.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Bajaj Healthcare Limited (BAJAJHCARE)?

Earnings per share at Bajaj Healthcare Limited are ₹7.39 (price ÷ EPS = P/E 44.0). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Bajaj Healthcare Limited (BAJAJHCARE)?

The dividend yield of Bajaj Healthcare Limited is 0.5% (payout 20.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Bajaj Healthcare Limited (BAJAJHCARE)?

The net margin of Bajaj Healthcare Limited is 3.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Bajaj Healthcare Limited (BAJAJHCARE)?

The return on equity (ROE) of Bajaj Healthcare Limited is 4.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Bajaj Healthcare Limited (BAJAJHCARE)?

On an EBIT basis the return on assets of Bajaj Healthcare Limited is 9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Bajaj Healthcare Limited (BAJAJHCARE)?

The operating margin of Bajaj Healthcare Limited is 13.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Bajaj Healthcare Limited (BAJAJHCARE)?

Revenue at Bajaj Healthcare Limited is growing +18.9% versus a year earlier (3y avg −1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Bajaj Healthcare Limited (BAJAJHCARE)?

Earnings per share at Bajaj Healthcare Limited are growing +20.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Bajaj Healthcare Limited (BAJAJHCARE) generate?

The free cash flow of Bajaj Healthcare Limited is −₹61.3M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Bajaj Healthcare Limited (BAJAJHCARE) carry?

The net debt of Bajaj Healthcare Limited is ₹2.1B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Bajaj Healthcare Limited in the live analysis

One click puts Bajaj Healthcare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.